Tick Boot Camp

Episode 546: When the Brain Pathobiome Becomes Personal: Polymicrobial Drivers of Cognitive Decline – Nicole Bell

Overview

This special episode of the Tick Boot Camp Podcast was recorded live at the 2nd Annual Alzheimer’s Pathobiome Initiative (AlzPI) and PCOM Symposium in collaboration with Pathobiome Perspectives. Hosted by Ali Moresco in partnership with Nikki Schultek (Executive Director, AlzPI), the conversation advances the Tick Boot Camp mission of exploring infection-associated chronic illness (IACI)—including Lyme disease and other tick-borne infections—within the global Alzheimer’s and neuroimmunology community.

Tick Boot Camp co-founders Matt Sabatello and Rich Johannesen partnered with Ali and Nikki to amplify voices connecting tick-borne illness, microbes, and cognitive decline. This episode features Nicole Bell—author, entrepreneur, and CEO of Galaxy Diagnostics—whose memoir What Lurks in the Woods documents her late husband Russ’s misdiagnosed tick-borne illness and their search for answers.

Guest

  • Nicole Bell
  • Author of What Lurks in the Woods
  • CEO, Galaxy Diagnostics
  • Advocate for tick-borne and neurodegenerative disease
  • BS/MS, Materials Science & Engineering (MIT)
  • MS, Biomedical Engineering (Duke University)

At the Symposium, Nicole presented “When the brain pathobiome becomes personal,” sharing her family’s journey and new findings from Russ’s donated brain: laboratory evidence of Borrelia burgdorferi, Chlamydia pneumoniae, and Babesia otocoli (a species long thought to be deer-restricted) in brain tissue—data now being prepared for publication. Researchers also noted elevated heavy metals (lead, mercury), underscoring how polymicrobial infection plus toxic exposures may converge to drive neuroinflammation and Alzheimer’s-like decline.

Key Discussion Points

Nicole details how repeated “normal” neurology workups masked a complex pathobiome process. She explains why standard two-tier Lyme serology can miss true infection, how direct detection can change care, and why patients should consider Bartonella and Babesia alongside Lyme. She outlines hallmark Bartonella clues—including striæ that resemble stretch marks (often more visible after hot showers), neuropsychiatric manifestations (irritability, anxiety, OCD, tics), ocular and joint involvement—and highlights non-tick vectors (notably fleas and household cats) that expand risk beyond forest exposure.

Nicole advocates for building a diagnostic toolkit that combines serology with sensitive direct tests to clarify which pathogens are active—critical because Borrelia, Bartonella, and Babesia require different treatment paradigms. Looking forward, she envisions comprehensive screening panels for midlife cognitive changes that integrate pathogen load, host immune signatures, and toxin status, enabling earlier, targeted interventions.

“Everyone wants a simple A→B. But the toughest chronic conditions are subtle and multifactorial. Accurate data, direct detection, and a clinician who will go on the journey with you can change everything.” — Nicole Bell

Why It Matters

Nicole’s story humanizes the science: polymicrobial infection + toxins + host factors can look “psychiatric” or “idiopathic” until modern testing reveals the underlying pathobiome. Her advocacy pushes medicine toward precision diagnostics, earlier detection, and pathogen-informed care that may prevent years of decline.

About the Event

Recorded at the 2nd Annual Alzheimer’s Pathobiome Initiative (AlzPI) and Philadelphia College of Osteopathic Medicine (PCOM) Symposium on October 3, 2025, at Ohio University (Dublin, Ohio). The meeting convened global experts investigating how microbes, the microbiome, and immune responses contribute to Alzheimer’s, dementia, PANS/PANDAS, and other infection-associated chronic illnesses (IACI). This episode is part of a Tick Boot Camp series connecting chronic Lyme research with cutting-edge brain-immune science.

Learn More

Episode 545: Using the Human Eye to Detect Early Alzheimer’s and Infection-Induced Brain Changes – Dr. Sean Miller (Yale)

Overview

This special episode of the Tick Boot Camp Podcast was recorded live at the 2nd Annual Alzheimer’s Pathobiome Initiative (AlzPI) and PCOM Symposium in collaboration with Pathobiome Perspectives. Hosted by Ali Moresco in partnership with Nikki Schultek, Executive Director of AlzPI, the conversation brings the Tick Boot Camp mission of exploring infection-associated chronic illness (IACI)—including Lyme disease and other tick-borne infections—to the global Alzheimer’s and neuroimmunology research community.

Tick Boot Camp co-founders Matt Sabatello and Rich Johannesen partnered with Ali and Nikki to highlight leading scientists connecting infection, immune dysfunction, and cognitive decline. This episode features Dr. Sean Miller, a neuroscientist and co-investigator in the Logan Lab with a primary appointment at Yale School of Medicine, who is developing ways to non-invasively detect Alzheimer’s-like pathology through the eye.

Guest

  • Sean Miller, PhD
  • Co-Investigator, Logan Lab / Yale School of Medicine

Dr. Sean Miller completed pre-doctoral work at Harvard Medical School, earned his PhD from Johns Hopkins University, and completed post-doctoral training at Stanford University. His research focuses on neurodegeneration, neuroglia, and early diagnostic strategies for Alzheimer’s and related diseases.

At the AlzPI & PCOM Symposium, Dr. Miller presented evidence showing that SARS-CoV-2 (COVID-19) infection can accelerate Alzheimer’s-like pathology and that these changes can be detected non-invasively through retinal imaging. His findings suggest that amyloid-beta, a protein long associated with Alzheimer’s disease, may also serve as part of the brain’s antimicrobial defense system—trapping pathogens like a mesh or biofilm, but leading to damaging plaque buildup when overproduced.

Key Discussion Points

Dr. Miller describes how the COVID-19 virus can act as an infectious trigger for neuroinflammation and amyloid buildup, how the eye provides a unique window into the brain, and why early detection is essential to preventing neuron death. He shares how his lab’s AI-enhanced retinal imaging research at Yale Eye Center is identifying amyloid and tau deposits in patients with long COVID-related brain fog—opening the possibility of routine eye exams doubling as early Alzheimer’s screening tools.

He explains potential therapeutic strategies, such as limiting amyloid production during infection flare-ups and enhancing clearance mechanisms afterward to reduce chronic plaque formation. The conversation also explores his scientific journey—from designing Alzheimer’s drugs at Harvard and Johns Hopkins to realizing the need for early disease detection during his postdoc at Stanford—and how the pandemic inspired his focus on infection-induced neurodegeneration.

“We believe neurons are exposed to pathogens in the central nervous system and respond by secreting amyloid-beta to trap them. Excessive plaque buildup from repeated or severe infections may be what drives long-term neurodegeneration.” — Dr. Sean Miller

Why It Matters

Dr. Miller’s research connects infectious disease, ophthalmology, and neurology, providing a revolutionary new method to screen for early Alzheimer’s-like changes non-invasively through the human eye. His work suggests that infections like COVID-19 may trigger the same protective—but damaging—immune responses implicated in chronic conditions such as Alzheimer’s disease and infection-associated cognitive decline.

About the Event

The interview took place at the 2nd Annual Alzheimer’s Pathobiome Initiative (AlzPI) and Philadelphia College of Osteopathic Medicine (PCOM) Symposium, held on October 3, 2025, at Ohio University in Dublin, Ohio. The event brought together more than 20 global researchers exploring how microbes, the microbiome, and the immune response contribute to Alzheimer’s, dementia, PANS/PANDAS, and infection-associated chronic illnesses (IACI).

Tick Boot Camp partnered with Ali Moresco and Nikki Schultek to share the voices of researchers advancing the field of infection-associated chronic illness. This episode is part of a multi-part Tick Boot Camp series highlighting how pathobiome and microbiome science are transforming the understanding of Lyme disease, infection, and neurodegeneration.

Learn More

Episode 544: How Microbes Like Lyme May Trigger Alzheimer’s and Cognitive Decline – Dr. Brian Balin (PCOM)

Overview

This special episode of the Tick Boot Camp Podcast was recorded live at the 2nd Annual Alzheimer’s Pathobiome Initiative (AlzPI) and PCOM Symposium in collaboration with Pathobiome Perspectives. Hosted by Ali Moresco in partnership with Nikki Schultek, Executive Director of AlzPI, the conversation brings the Tick Boot Camp mission of exploring infection-associated chronic illness (IACI), like Lyme disease and other tick-borne diseases, to the global Alzheimer’s and neuroimmunology research community.

Tick Boot Camp co-founders Matt Sabatello and Rich Johannesen partnered with Ali and Nikki to highlight scientists whose work connects tick-borne illness, microbes, and cognitive decline. This episode features Dr. Brian J. Balin, an internationally recognized neuroscientist whose research has redefined the role of infection in contributing to Alzheimer’s disease.

Guest

  • Brian J. Balin, PhD
  • Professor of Neuroscience and Neuropathology
  • Director, Center for Chronic Disorders of Aging
  • Philadelphia College of Osteopathic Medicine (PCOM)

Dr. Balin directs the Center for Chronic Disorders of Aging and the Adolph and Rose Levis Foundation Laboratory for Alzheimer’s Disease Research at PCOM. With a PhD from the University of Maryland School of Medicine and postdoctoral training at the University of Pennsylvania, he has devoted nearly three decades to understanding how chronic infection and inflammation trigger neurodegeneration.

His pioneering discovery that the respiratory bacterium Chlamydia pneumoniae infects brain tissue helped establish the Pathogen Hypothesis of Alzheimer’s disease. His continuing work explores how tick-borne microbes — including Borrelia burgdorferi (Lyme disease), Bartonella, and Babesia — interact with other pathogens to drive neuroinflammation and cognitive decline.

Key Discussion Points

  • How infections such as Chlamydia pneumoniae, Borrelia burgdorferi, Bartonella, and Babesia were detected in Alzheimer’s brain tissue.
  • Evidence that microbes can enter the brain via the olfactory pathway or blood-brain barrier, initiating chronic inflammation, amyloid plaque formation, and tau tangle pathology.
  • Findings from Dr. Balin’s collaboration with Galaxy Diagnostics and advocate Nicole Bell, revealing polymicrobial infection and even Babesia otocoli — a strain previously believed to infect only deer — in human brain tissue.
  • The use of animal models and 3D human brain organoids to study infection-driven neurodegeneration.
  • Why identifying infection as part of the exposome (environmental insults over a lifetime) is key to developing precision diagnostics and treatments.
  • Future directions: immune-modulating drugs, antimicrobials, and emerging phage therapy.

“Infection is part of the exposome — an environmental insult that shapes our health over a lifetime. Recognizing that is key to truly understanding and preventing Alzheimer’s disease.” — Dr. Brian J. Balin

Why It Matters

Dr. Balin’s research bridges the worlds of neurology and infectious disease, offering a framework that could revolutionize how Alzheimer’s and other neurodegenerative conditions are diagnosed and treated. By recognizing that microbes — including those transmitted by ticks — can initiate neuroinflammation and cognitive decline, his work provides hope for millions living with infection-associated chronic illness.

About the Event

The interview took place at the 2nd Annual Alzheimer’s Pathobiome Initiative (AlzPI) and Philadelphia College of Osteopathic Medicine (PCOM) Symposium, October 3, 2025, Ohio University in Dublin, Ohio. The Symposium brought together more than 20 experts exploring how microbes, the microbiome, and the host immune response contribute to neurological and psychiatric diseases such as Alzheimer’s, dementia, and PANS/PANDAS.

Tick Boot Camp partnered with Ali Moresco and Nikki Schultek to document and share the voices of scientists advancing research on infection-associated chronic illness (IACI). This episode is part of a special series showcasing how pathobiome and microbiome science is changing our understanding of chronic Lyme and neurodegenerative disease.

Learn More

Episode 543: Measuring Brain Fog in Infection-Associated Chronic Illnesses (IACI) - an interview with MIT Researcher Yuri Kim

Overview

This special episode of the Tick Boot Camp Podcast was recorded live at the 2nd Annual Alzheimer’s Pathobiome Initiative (AlzPI) and PCOM Symposium in collaboration with Pathobiome Perspectives. Hosted by Ali Moresco in partnership with Nikki Schultek, Executive Director of AlzPI, the conversation brings the Tick Boot Camp mission of exploring infection-associated chronic illness (IACI)—like Lyme disease and other tick-borne infections—to the global Alzheimer’s and neuroimmunology research community.

Tick Boot Camp co-founders Matt Sabatello and Rich Johannesen partnered with Ali and Nikki to highlight scientists whose work connects tick-borne illness, microbes, and cognitive decline. This episode features Yuri Kim, RN, Lead Clinical Research Nurse for the MAESTRO Study at the Massachusetts Institute of Technology (MIT), who is leading pioneering work to measure and understand “brain fog” in infection-associated chronic illness.

Guest

  • Yuri Kim, RN
  • Lead Clinical Research Nurse, MAESTRO Study
  • Massachusetts Institute of Technology (MIT)

Yuri Kim is the Lead Clinical Research Nurse for the MAESTRO Study, the largest clinical study ever conducted at MIT, led by Dr. Michal “Mikki” Caspi Tal, immunologist and immunoengineer at the Massachusetts Institute of Technology. The MAESTRO Study investigates infection-associated chronic illnesses (IACI) such as chronic Lyme disease and aims to objectively measure and understand one of the most debilitating and misunderstood symptoms—brain fog.

Yuri has conducted more than 170 participant study visits and integrates patient narratives with advanced neurocognitive, immune, and molecular profiling. Her background includes experience as a trauma ER nurse and clinical research manager on neurodegenerative and rare diseases such as Alzheimer’s disease, chronic traumatic encephalopathy (CTE), and amyloidosis.

Key Discussion Points

  • How the MAESTRO Study combines subjective patient narratives with objective neurocognitive and biomarker data to better define and measure brain fog.
  • Use of innovative diagnostic tools including EEG (WAVi), RightEye eye-tracking, BrainCheck cognitive testing, and NASA Lean autonomic assessments.
  • Early findings showing slower reaction times and potential correlations between GFAP, NfL, and sCD14 with cognitive symptoms in chronic Lyme and other IACI patients.
  • The role of immune dysregulation, gut permeability, and neuroinflammation in contributing to cognitive impairment.
  • The need for brain fog-specific assessment tools and more research into sex and hormonal differences that may affect neurocognitive outcomes.
  • Why validating and quantifying “invisible symptoms” is vital to patient care and the future of infection-associated chronic illness research.

“Brain fog isn’t just a symptom—it’s a phenomenon interconnected with multiple systems. We’re trying to narrow the gap between what patients report and what we can measure.” — Yuri Kim

Why It Matters

Yuri Kim’s work at MIT bridges patient experience and advanced science to address one of the most misunderstood symptoms in infection-associated chronic illness: brain fog. Her research within the MAESTRO Study, under the leadership of Dr. Michal “Mikki” Caspi Tal, is generating objective evidence that validates patient experiences and reveals how chronic infection and immune dysregulation can cause measurable cognitive and physiological changes.

By studying infection-associated brain fog in Lyme disease and other chronic conditions, Yuri and the MAESTRO team are helping to shape a new era of diagnostics and care for people living with long-term, infection-driven illness.

About the Event

The interview took place at the 2nd Annual Alzheimer’s Pathobiome Initiative (AlzPI) and Philadelphia College of Osteopathic Medicine (PCOM) Symposium, held on October 3, 2025, at Ohio University in Dublin, Ohio. The Symposium brought together more than 20 international experts investigating how microbes, the microbiome, and the host immune response contribute to neurological and psychiatric conditions such as Alzheimer’s, dementia, and PANS/PANDAS.

Tick Boot Camp partnered with Ali Moresco and Nikki Schultek to capture and share the voices of scientists advancing research on infection-associated chronic illness (IACI). This episode is part of a special Tick Boot Camp series spotlighting how pathobiome and microbiome science are transforming the understanding of chronic Lyme, cognitive dysfunction, and neurodegeneration.

Learn More

Episode 542: Z3LLA - Using Lyme Disease to Redefine Resilience in the Music Industry

In this powerful episode of the Tick Boot Camp Podcast, international DJ and artist duo Z3LLA — Julia “Juj” Seeley and Kiana Tebyani — share how chronic illness, creativity, and friendship became the foundation of their success.

After years of unexplained symptoms, Juj was diagnosed with Lyme disease, Bartonella, Babesia, mold toxicity, POTS, SIBO, celiac disease, and later catamenial epilepsy. Despite life-altering health challenges, she and her best friend Kiana have built Z3LLA into one of the most exciting names in house music — with their single “Why Should I?” reaching #1 on the US Dance Radio Charts and performances alongside Disco Lines, Galantis, and Bijou.

Together, Juj and Kiana discuss performing through flare-ups, collapsing backstage, navigating the medical system, and the emotional toll of chasing dreams while managing invisible illness. From ER visits and red-light therapy to steroid crashes and spiritual breakthroughs, this episode is a masterclass in resilience, vulnerability, and using art as advocacy.

🌿 Episode Highlights

  • The early years: Celiac diagnosis, chronic rashes, and the path to discovering Lyme, Bartonella, and Babesia
  • Treating the terrain: Mold toxicity and inflammation as hidden barriers to healing
  • Neurological challenges: Catamenial epilepsy, seizures, and functional brain inflammation
  • Functional medicine approach: Working with Dr. Nicola Ducharme on hormone balance, gut repair, and detox
  • Touring through illness: Allergic reactions mid-set, paramedics at Miami Music Week, and a hospital trip after the Fonda Theatre show
  • Women’s health gaps: Misdiagnosis, heavy cycles, iron infusions, and the impact of hormonal disruption
  • The LymeLightFoundation’s impact: Lyme disease treatment grants that helped fund advanced Lyme treatments for Juj
  • Friendship and balance: How Kiana became Juj’s anchor on the road and in recovery
  • Boundaries in advocacy: Protecting mental health and avoiding trauma bonding in chronic illness communities
  • The creative future: Plans for a Lyme awareness festival (“LymeStock”), composing for film, and writing a book

💬 Notable Quotes

  • “I was so tired of band-aid medicine — I needed to heal, not just survive.” – Juj Seeley
  • “She’s the definition of perseverance. You’d never know she was hallucinating from exhaustion one night and headlining a sold-out show the next.” – Kiana Tebyani
  • “Consistency is the key to natural healing — the herbs, the detox, the mindset. You have to commit.” – Matt Sabatello
  • “Our art is advocacy. The music tells the story.” – Z3LLA

🔑 Key Topics

  • Chronic Lyme and co-infections (Babesia, Bartonella)
  • Mold toxicity and inflammatory overlap
  • Neurological Lyme and epilepsy (catamenial pattern)
  • Women’s health and hormone regulation
  • Gut healing, celiac management, and SIBO protocols
  • Red light therapy, sauna detox, and lymphatic movement
  • Touring while chronically ill
  • Functional medicine and integrative treatment approaches
  • Mental health, boundaries, and advocacy sustainability
  • Female empowerment in the music industry

💡 Lessons & Takeaways

  • Healing isn’t linear — progress comes in waves, not straight lines.
  • Female artists with chronic illness face unique visibility and credibility challenges.
  • Addressing inflammation and mold toxicity is often the missing step in long-term recovery.
  • Community support and funding — like the Limelight Foundation — can change treatment access.
  • Creative expression is not separate from healing; it’s often part of it.

🎶 About Z3LLA

Z3LLA is an award-winning artist/DJ duo composed of Julia “Juj” Seeley and Kiana Tebyani, two vocalists, songwriters, and producers redefining what it means to thrive as women in electronic music. Known for their infectious energy and empowering message, Z3LLA’s breakout single “Why Should I?” hit #1 on the US Dance Radio Charts, with spins on SiriusXM BPM, Music Choice, and Evolution Radio. They’ve shared the stage with Disco Lines, Galantis, and Bijou, earned the Level Future of Dance Award from Nexus Radio, and performed at Miami Music Week and beyond. With an authentic blend of vulnerability and power, Z3LLA is not just creating music — they’re building a movement.

Follow Z3LLA: 🎧 Spotify | 📸 Instagram | 🎵 Apple Music | 🌐 YouTube

🔗 Resources Mentioned

Episode 541: Dr. Myriah Hinchey: Inside the LymeBytes Symposium 2025 – Fast-Tracking Healing for Lyme and Chronic Illness

Episode Summary

In this special Tick Boot Camp Podcast episode, Dr. Myriah Hinchey (ND) joins Matt Sabatello and Rich Johannesen from Tick Boot Camp to spotlight the 2025 LymeBytes Symposium, a physician- and patient-focused conference designed to shorten the healing journey for Lyme, mold illness, PANS/PANDAS, Long COVID, and other complex, infection-driven chronic conditions. We dig into why immersive learning accelerates progress, how an intimate format fuels direct access to top clinicians and vendors, and what attendees—both in-person and virtual—will actually experience over two packed days in Fort Lauderdale.

  • Exclusive Listener Offer: Use code TBC100 at checkout for $100 off in-person or virtual tickets at shop.lymebytes.com.

Why This Episode Matters

  • End the isolation: Dr. Hinchey explains how community, validation, and shared learning unlock momentum for both patients and clinicians.
  • Immersion = speed: Concentrated exposure to leading experts and technologies helps you discover the next best step faster.
  • Bridging the gap: Learn why precision care often requires a team—LLMDs, specialty labs, compounders, targeted supplements, and therapeutic devices—working together.

What You’ll Learn

  • Inside the LymeBytes philosophy: Healthy, gluten- and dairy-free meals, beach-side community dinner, structured networking, and vendor access that mirror the lifestyle principles used in treatment.
  • Adjunctive therapies on site: Demos and education around hyperbaric oxygen therapy (OxyHealth), infrared/red light, Relax Sauna, Therasage, plus niche supplement brands (e.g., Alight by Dr. Jill Crista, NutraMedix, Lymecore Botanicals) and specialty labs for Lyme, co-infections, and mold.
  • Precision testing & interpretation: Why test results (e.g., Western Blots, specialty panels) must be read in clinical context, and how collaboration between vendors and clinicians personalizes care.
  • PRP/TruDose spotlight: A primer on platelet-rich plasma (PRP) and how TruDose aims to reset immune function and calm the nervous system using your own platelets—plus a teaser for a future deep-dive episode.
  • Virtual experience (no FOMO): Live access to all clinician lectures, slides, full-day recordings to rewatch/scrub, and new vendor mini-interviews so remote attendees don’t miss the expo value.

Who Should Attend the Symposium

  • Patients & caregivers seeking credible, actionable strategies to shorten recovery time
  • Clinicians (conventional, integrative, functional) looking to upgrade protocols for chronic infection and inflammation
  • Allies & advocates ready to learn the truth about Lyme and related conditions from top voices in the field
  • Anyone who wants direct access to vendors, labs, and tools that often stay off patients’ radars

Event Details (In-Person + Virtual)

  • Dates: November 14–15, 2025
  • Location: Fort Lauderdale Marriott Pompano Beach Resort & Spa (Florida)
  • Format: Limited-capacity, intimate event (≈180–200 attendees) fostering direct interaction with clinicians, researchers, and vendors
  • Perks: Healthy meals (GF/DF), Friday night beach dinner, curated vendor hall, 14.5 CME credits available in person (additional fee)
  • Virtual: Live stream + full-day recordings (Day 1 & Day 2), slide access, vendor mini-features
  • Register: shop.lymebytes.com
  • $100 Off: Use code TBC100 at checkout (in-person or virtual)

Notable Quotes

  • On immersion: “The more volume of opportunities in an immersive environment, the more your internal diagnostic system can sense what resonates—and that’s often your next right step.”
  • On community: “Patients and clinicians are often dismissed or isolated. This event builds real connections you can rely on after you go home.”
  • On precision: “Chronic cases are outliers—they need specialized testing, targeted supplements, and coordinated care to get unstuck.”

Call to Action

If travel isn’t possible, don’t wait—join virtually to access the same lectures, slides, and full-day recordings. And if you can make it to Florida, come say hi to Rich and the Tick Boot Camp crew in person.

👉 Register now: shop.lymebytes.com | Use code TBC100 for $100 off.

Episode 540: Dr. Bill Rawls on Chronic Lyme, Herbs, Gut Health, and Stepwise Recovery at Project Lab Coat, New York Fashion Week

Recorded in person in Central Park, NYC just before Project Lab Coat at New York Fashion Week (NYFW), this Tick Boot Camp Podcast features Dr. Bill Rawls on what helps chronic Lyme patients move from overwhelm to progress. We talk immune-first strategy, why antibiotics often fall short in chronic cases, how to protect the gut, and a stepwise plan that reduces flare risk and builds confidence.

Episode snapshot

Dr. Rawls explains why stealth microbes like Borrelia, Bartonella, and Babesia grow slowly and hide in tissues, which is why a quick-fix antibiotic approach often disappoints in chronic illness. We discuss a four-phase healing framework — prehabilitation, assist the immune system, rehabilitation, and maintenance (PARM) — and how a gradual, system-calming on-ramp helps patients tolerate protocols without crashing. We also dig into gut protection, community support, and how AI can speed education and research.

What you will learn

  • Why “assist the immune system” beats “kill at all costs” for chronic Lyme
  • Stealth microbe biology and why slow growth changes the treatment playbook
  • Antibiotic overuse risks including microbiome injury and antibiotic resistance
  • Gut and detox support as foundations for energy, sleep, and resilience
  • A stepwise entry to treatment that reduces flares and anxiety
  • Key herbs with evidence for tick-borne infections and immune modulation
  • Community and education as levers for consistency and long-term success
  • How AI tools can accelerate research, writing, and practical guidance

Key topics and takeaways

  • Four phases of recovery: prehab, assist, rehab, maintenance
  • Antibiotics in chronic Lyme: may disrupt the gut before meaningfully impacting slow-growing pathogens
  • Herbal strategy: sustained pressure over time with immune support
  • Gradual on-ramp: calm the nervous system first, then gut and detox, then stronger antimicrobials
  • Team sport: combine self-care, educated use of providers, and moderated community support

Herbs and supports mentioned

  • Antimicrobial herbs: Japanese knotweed, Chinese skullcap, Cryptolepis, cat’s claw, garlic
  • Immune-modulating adaptogens: reishi, cordyceps
  • Supportive nutrients: B vitamins, minerals, NAC, glutathione
  • Formats: capsules and tinctures were discussed, including products like Advanced Biotic and Biome Boost within larger protocols

Patient-friendly pacing

  • Months 1–2: calm sympathetic overdrive, improve sleep, stabilize
  • Months 3–4: protect gut, support detox, keep gentle antimicrobial pressure
  • Months 5–6: advance to stronger combinations when the body is ready
  • Ongoing: measure progress, maintain gain, prevent backsliding

Notable quotes

  • “The immune system always wins the game. Your job is to assist it.”
  • “Stealth microbes grow slowly and hide in tissues. The strategy has to match the biology.”
  • “Education and a supportive community reduce fear and make consistency possible.”

Resources and links

Episode 539: Geoff Dow on Babesiosis: Malaria Parallels, Tafenoquine (Arakoda), and New Clinical Trials for Chronic Tick-Borne Disease

Dr. Geoff Dow, CEO of 60 Degrees Pharmaceuticals and former malaria drug developer at Walter Reed, joins the Tick Boot Camp Podcast to unpack the science and strategy behind treating babesiosis.

Drawing parallels to malaria, Dow explains why tafenoquine (brand: Arakoda), FDA-approved for malaria prevention, is being studied for Babesia, how coinfections (Borrelia, Bartonella) complicate care, and why chronic illness needs a different clinical approach.

He previews an upcoming Mount Sinai trial for chronic babesiosis focused on fatigue outcomes and discusses real-world diagnostics using FDA-approved blood donor screening plus PCRs from Galaxy Diagnostics and Mayo Clinic.

The conversation also touches on prophylaxis concepts, immune dysregulation, and building a clearer path from anecdote to evidence for the tick-borne disease community.

Guest

Geoff Dow, BSc, MBA, PhD CEO & Board Member, 60 Degrees Pharmaceuticals Background: Biotechnology (Perth, Australia), PhD in malaria drug discovery, decade at Walter Reed Army Institute of Research, MBA in the U.S. Leads clinical programs exploring tafenoquine for babesiosis.

Key Topics & Takeaways

  • Malaria ↔ Babesiosis Parallels: Both are red-blood-cell parasites; acute symptoms driven by red cell destruction. Similar drug targets justify testing some anti-malarials against Babesia.
  • Why Tafenoquine (Arakoda): An 8-aminoquinoline that induces oxidative stress in RBCs; distinct mechanism from atovaquone + azithromycin combo (current standard for acute babesiosis), potentially useful for resistance management.
  • Chronic vs. Acute Disease: Acute babesiosis in immunocompetent patients often responds to standard care; chronic illness remains under-defined and underserved.
  • Coinfections Are Common: Many chronically ill patients present with Borrelia, Bartonella, and Babesia together; diagnostics and treatment need to acknowledge polymicrobial reality.
  • Upcoming Clinical Trial (Mount Sinai):
  • Population: Chronic babesiosis with disabling fatigue, plus Babesia symptoms (e.g., air hunger, anemia) and lab evidence in the last 12 months.
  • Regimen: 4-day loading dose then 200 mg weekly of tafenoquine for 3 months.
  • Outcomes: Patient-reported fatigue (quality-of-life) + monthly molecular testing (FDA blood donor test, Galaxy Diagnostics PCR, Mayo Clinic PCR) during treatment and 3 months post-therapy.
  • Goals: Demonstrate symptom improvement, assess eradication signals, and validate accessible diagnostics against an FDA-accepted assay.
  • Prophylaxis & Post-Exposure Ideas: Animal data suggest short-course tafenoquine can eradicate early Babesia; human prophylaxis trials face feasibility and regulatory hurdles.
  • Diagnostics Gap: Need for standardized, sensitive tools to define chronic babesiosis and track response. This trial also serves as a real-world diagnostic comparison.
  • Immune Dysregulation & IACI: Overlap among long COVID, ME/CFS, post-treatment Lyme—shared theme of immune dysregulation with possible persistent antigen stimulation.
  • Safety Notes: G6PD deficiency is relevant to 8-aminoquinolines; established safety database exists for malaria prevention dosing—critical as studies expand to babesiosis.

Notable Quotes

  • “You’ve got to put some lines in the sand—run the trial, collect data, and move the field forward.”
  • “The best we can do for chronic disease starts with defining it—and validating the diagnostics we use to track it.”
  • “8-aminoquinolines offer a different mechanism than current babesiosis standards—key for resistance and combinations.”

Resources Mentioned

  • Arakoda (tafenoquine): FDA-approved for malaria prevention; under study for babesiosis.
  • Diagnostics: FDA-approved Babesia blood donor screen; Galaxy Diagnostics PCR; Mayo Clinic PCR.
  • Organizations & Events: ILADS, Global Lyme Alliance, tick-borne disease conferences.
  • Research Partners: Mount Sinai (NYC), Tulane University (Bartonella/Borrelia collaboration).

Who Should Listen

  • Patients with chronic Lyme or chronic babesiosis symptoms (fatigue, air hunger, anemia)
  • Clinicians seeking updates on Babesia treatment research and diagnostics
  • Caregivers and advocates tracking IACI and immune dysregulation science
  • Researchers exploring antimalarial repurposing for tick-borne diseases

Call to Action

  • Subscribe to Tick Boot Camp and share this episode with someone navigating chronic tick-borne illness.

Episode 538: NYFW Project Lab Coat - Col. Nicole Malachowski on Lyme IACI and the National Academies Report on Chronic Lyme Disease

In this special Tick Boot Camp Podcast episode recorded live at Project Lab Coat during New York Fashion Week (NYFW), we sit down with Colonel Nicole Malachowski, USAF (Ret.).

Col. Malachowski, the first female pilot of the USAF Thunderbirds and a Lyme patient advocate, walked the runway with us at Project Lab Coat and served as the sole patient representative on the National Academies of Sciences, Engineering, and Medicine committee that authored the landmark report on Lyme infection-associated chronic illness (Lyme IACI).

She shares her perspective on why this recognition is a historic milestone for the Lyme community.

What You’ll Learn in This Episode

  • Why the term Lyme IACI (infection-associated chronic illness) matters and how it creates an inclusive umbrella for persistent symptoms after Lyme infection.
  • How the National Academies report represents the first time the U.S. government has officially recognized Lyme IACI.
  • What it was like for Col. Malachowski to serve as the sole patient representative on the committee alongside scientists and clinicians.
  • Why the report calls for running treatment trials in parallel with biomarker discovery so patients are not left waiting.
  • How collaboration with long COVID and ME/CFS communities can accelerate solutions and strengthen advocacy.
  • The role of AI and machine learning in analyzing patient data, biobanks, and surveys to identify new diagnostics and repurposed therapies.
  • Why visibility at NYFW Project Lab Coat signals growing mainstream recognition of Lyme disease.

About Col. Nicole Malachowski

Col. Malachowski is a retired U.S. Air Force fighter pilot, the first woman selected to fly with the USAF Thunderbirds, and a National Women’s Hall of Fame inductee. After contracting a tick-borne illness and being medically retired, she became a nationally recognized speaker and advocate for Lyme patients. She served as the sole patient voice on the National Academies committee that authored the landmark report on Lyme IACI, commissioned with support from the Steven & Alexandra Cohen Foundation.

About Project Lab Coat at New York Fashion Week

Project Lab Coat was a groundbreaking event held on September 13, 2025, during New York Fashion Week (NYFW). The show brought together prominent celebrities, researchers, doctors, and advocates who were invited to walk the runway to spotlight Lyme disease and raise funds for Lyme disease research.

For the first time, the global visibility of NYFW was used to highlight one of the fastest-growing infectious diseases in the world. Tick Boot Camp co-founders Matt Sabatello and Rich Johannesen, together with Dr. Tal, walked the runway at Project Lab Coat, joining leaders from medicine, science, entertainment, and advocacy. Project Lab Coat demonstrated the power of mainstream platforms to bring awareness, credibility, and resources to the fight against Lyme disease.

Key Takeaways

  • Federal recognition matters – Lyme IACI in a National Academies report marks a turning point in credibility and urgency.
  • Patients at the center – clinical trials must include patients from design through reporting.
  • Collaboration is key – linking Lyme, long COVID, ME/CFS, and other infection-associated conditions strengthens progress.
  • Do both now – pursue biomarkers and cures while also running treatment studies to help patients immediately.
  • Technology accelerates hope – AI and machine learning can unlock insights from existing patient data.

Resources and Links

Episode 537: NYFW Project Lab Coat - MIT Immunologist Dr. Michal Caspi Tal on Chronic Lyme, Immune Responses, and Hope for Patients

In this special Tick Boot Camp Podcast episode recorded live at Project Lab Coat during New York Fashion Week (NYFW), we sit down with Dr. Michal “Mikki” Caspi Tal, Principal Scientist in the Department of Biological Engineering at MIT and Associate Scientific Director of the MIT Center for Gynepathology Research.

Dr. Tal is an immunologist and immunoengineer whose groundbreaking research focuses on the connections between infections and chronic diseases, including Lyme disease and long COVID. At her Tal Research Group lab, she studies why some people recover quickly after infection while others develop chronic illness, with a focus on the immune system’s different responses in men and women.

What You’ll Learn in This Episode

  • How Dr. Tal’s lab uses mouse models of chronic Lyme and a large clinical study to take a deeper look at Lyme disease.
  • Why some patients make a protective immune response while others develop catastrophic responses like dysautonomia, MCAS, gynecological issues, or clotting disorders.
  • How her team is moving beyond “yes/no” antibody tests to create new biomarker diagnostics that can guide treatments.
  • Why sex differences matter in chronic illness and why women are more likely to experience long-term symptoms after infection.
  • How her research could lead to more personalized treatment approaches for Lyme disease patients by grouping individuals based on immune response patterns.
  • What samples (blood, saliva, sweat, tissue) her team is collecting at MIT to uncover new insights into chronic Lyme disease.
  • Why this research brings hope to Lyme patients who feel unseen and unheard.

About Dr. Michal Caspi Tal

  • Principal Scientist, MIT Department of Biological Engineering
  • Associate Scientific Director, MIT Center for Gynepathology Research
  • Focus areas: Lyme disease, long COVID, chronic inflammatory diseases, sex differences in immune response, predictive diagnostics
  • Background: PhD in Immunobiology from Yale (mentored by Dr. Akiko Iwasaki), postdoctoral training at Stanford (Irving Weissman lab), infectious disease research leader at Stanford’s Institute for Stem Cell Biology and Regenerative Medicine.
  • Awards: NIH NIAID F31 and F32 Fellowships, Bay Area Lyme Foundation Emerging Leader Award

About Project Lab Coat at New York Fashion Week

Project Lab Coat was a groundbreaking event held on September 13, 2025, during New York Fashion Week (NYFW). The show brought together prominent celebrities, researchers, doctors, and advocates who were invited to walk the runway to spotlight Lyme disease and raise funds for Lyme disease research.

For the first time, the global visibility of NYFW was used to highlight one of the fastest-growing infectious diseases in the world. Tick Boot Camp co-founders Matt Sabatello and Rich Johannesen, together with Dr. Tal, walked the runway at Project Lab Coat, joining leaders from medicine, science, entertainment, and advocacy. Project Lab Coat demonstrated the power of mainstream platforms to bring awareness, credibility, and resources to the fight against Lyme disease.

Why This Episode Matters

For too long, chronic Lyme patients have been told their symptoms are “all in their head.” Dr. Tal’s work at MIT proves otherwise by measuring the real biological differences in immune system responses. This research not only validates patients’ experiences but also charts a course toward better diagnostics, clinical trials, and personalized treatments.

The goal of the Tick Boot Camp Podcast is to help people liberate themselves and others from suffering caused by Lyme disease through validation, community building, belief that healing is possible, and modeling success. Listen to our Tick Boot Camp podcast using all major podcast streaming services such as Apple Podcasts, Spotify, and YouTube Music. Our podcast is also integrated with smart home devices, such as Amazon Alexa and Apple TV. Ask your device to "play the Tick Boot Camp Podcast!"